Dr Reddy's Brings In Kikuchi To Lead North America Generics
Dr Reddy’s has added to its senior leadership team by appointing Marc Kikuchi as CEO of North America Generics. With a record number of US launches in Q3, potentially more in store and now a new leader to steer things through, the firm has improved its outlook for a significant revival in earnings. But risks of delays and competition on certain key anticipated launches in 2019 could dull prospects.
You may also be interested in...
Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.
Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.
Dr Reddy’s is expanding its portfolio by acquiring 42 ANDAs in the US as it seeks to develop its North American and emerging market operations.